PP173—CyTiSiN AmidoPhoSPhATe ShowS hePAToPRoTeCTiVe effeCT

e72 Volume 35 Number 8S in severely obese diabetic patients having BS versus conventional/intensive antidiabetic therapy. Respectively, in these trials: patient numbers were 60 and 150, primary end points were 2-year HBA1C level ≤6.5% (with fasting glucose < 100 mg/dL and no anti-DM pharmacotherapy) and 1-year HBA1C levels ≤6%, and surgical interventions were gastric bypass and bilio-pancreatic diversion and gastric bypass and sleeve gastrectomy. As previously described, we calculated respective unadjusted RC (akin to relative risk), NNT, and 95% CI values. Results: The patients in these trials did not suffer any serious complications from their BS. Respective RC, NNT, and corresponding (CI) values were 8.5 (2.0–36.4) and 1.33 (1.08–1.74) and 3.2 (1.2–8.4) and 3.68 (2.42–7.68). Conclusion: In the short-term (1–2 years), BS was a highly effective means of eliminating DM in these patients. The perceived success rate depended on the precise criteria used to define diabetes and the type of BS, but due to small sample sizes apparent statistical significance cannot be discerned with confidence. Disclosure of Interest: None declared.